ND

Nicolas Deleye

Director International Business Development at Flen Health

Nicolas Deleye has an extensive background in international business development and sales within the pharmaceutical industry. Currently serving as the Director of International Business Development at Flen Health since July 2019, Nicolas previously held key positions as International Business Development Manager. Prior experience includes ten years at Qualiphar NV and Laboratoire Gifrer, where roles included International Sales Manager for North Europe and Central & North America, as well as Export Manager for Europe. Earlier in the career, Nicolas was the Responsible Pharmacist at Socobom NV. Nicolas's educational credentials include studies at the University of Antwerp and Ghent University, culminating in a high school diploma with a focus on Mathematics and Science from Sint-Barbaracollege Gent.

Links


Org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


Flen Health

Flen Health Live the Life you love! Flen Health believes biotech innovations can help to build a securer life for you and for every human being. Flen Health wants to improve the quality of life of people suffering from skin disorders in a responsible way, by providing added value for patients, healthcare professionals, health authorities and the environment. Flen Health was established in 2000, building on the results of wound-treatment research performed by its managing director, Philippe Sollie, a pharmacist. Based on patented technologies, Flen Health developed and commercializes a number of innovative wound and skin healing solutions. Flen Health holds an ISO 13485 certificate that covers all its operations. Thanks to the success on the Belgian market, Flen Health initiated its international expansion. This resulted in the establishment of further affiliates across Europe (in The Netherlands, Luxembourg, UK & Germany), managed by over 100 motivated employees. Flen Health products are distributed in 25 countries all over the world. Current product portfolio: Flaminal® Hydro, Flaminal® Forte, Flamigel®, Flamigel®RT, Flamirins® and extracalm®. Direct customers are mainly healthcare professionals: Flaminal® Hydro/Forte indicated for all kind of wound treatments and Flamigel® RT for skin damage caused by radiotherapy. Flen Health continues to expand its activities and invites motivated and dynamic people to join. Feel welcome to visit our website for more information:


Employees

51-200

Links